Zimmer Biomet Holdings 주식 (NYSE: ZBH)

Zimmer Biomet Holdings (NYSE:ZBH) 주식

ZIMMER BIOMET HOLDINGS INC

Zimmer Biomet Holdings

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings Inc

President Donald Trump announced tougher-than-anticipated tariffs on Wednesday, but there are some <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">notable exemptions</a>.
Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff <a href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" target="_blank" rel="noreferrer noopener">on pharmaceutical imports</a>. 
&#8220;The United States can no longer produce enough antibiotics to treat our sick,&#8221; Trump said Wednesday. &#8220;We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn&#8217;t be able to do it.&#8221;
The biopharma industry has historically been shielded from tariffs, including during Trump's first term. Investors had feared global tariffs could disrupt the sector, given its significant manufacturing presence in Europe. The Morningstar <a target="_blank" href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" rel="noreferrer noopener">report</a> says that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have resulted in a $20 billion cost to the industry, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs" rel="noreferrer noopener">Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs</a>
Per the Morningstar report on Thursday, a future global tariff on pharmaceuticals remains a risk despite the exemption, potentially pressuring gross margins and long-term tax rates. Companies may need to adjust their manufacturing strategies, though large-cap biopharma firms are expected to maintain strong economic positions. Tariffs could drive near-term margin pressures and lead to long-term U.S. manufacturing investments.
However, new facilities would take years to gain approval, especially with ongoing FDA staff <a href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" target="_blank" rel="noreferrer noopener">reductions affecting inspections</a>. If U.S. manufacturing increases, corporate tax rates could rise closer to the current 21% rate &#8211; a level Trump aims to maintain through the Republican-controlled Congress.
However, the medical device industry has not been spared, with diabetes device makers appearing to be the hardest hit.
Diabetes device manufacturers, including Dexcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Insulet Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) are among the most affected.
Larger cardiac and orthopedic device makers, such as Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) and Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) have seen minimal share movement and are expected to shift manufacturing to mitigate tariff effects.
The report <a href="https://www.morningstar.com/stocks/medical-device-industry-swept-up-tariffs-diabetes-device-makers-bear-brunt" target="_blank" rel="noreferrer noopener">notes</a> that among diabetes device makers, Tandem Diabetes appears particularly vulnerable due to its reliance on foreign components and manufacturing, limiting its ability to shift production.
The sector could face further challenges if European competitors, such as Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) and Ypsomed, gain an advantage or if Europe imposes reciprocal tariffs, intensifying competitive pressures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44647281/fda-approves-amgens-uplizna-as-first-drug-for-chronic-immune-mediated-fibroinflammatory-disorder" target="_blank" rel="noreferrer noopener">FDA Approves Amgen&#8217;s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

News

Health Care

General

DXCM

PODD

RHHBY

TNDM

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 11.66% since its last report. The company recently reported that it has 6.22 million shares sold short, which is 3.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742998516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Zimmer Biomet Holdings's Recent Short Interest

Paragon 28, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) ("Zimmer Biomet").

Paragon 28 Announces Expiration of HSR Act Waiting Period For Pending Acquisition By Zimmer Biomet Under HSR Act

Zimmer Biomet Receives FDA Clearance For Persona Revision SoluTion Femur, Offering Alternative For Patients With Metal Sensitivities

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 4.72% since its last report. The company recently reported that it has 7.07 million shares sold short, which is 4.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740758436_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 3.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Zimmer Biomet Holdings?

Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $123.44, a high estimate of $140.00, and a low estimate of $112.00. This current average represents a 1.59% decrease from the previous average price target of $125.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1739221223_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$113.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$112.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$119.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$128.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zimmer Biomet Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Zimmer Biomet Holdings's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Zimmer Biomet Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.03% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.98%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.15%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Zimmer Biomet Holdings Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

Truist Securities analyst Richard Newitter reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $118 to $113.

Price Target

Reiteration

Truist Securities Reiterates Hold on Zimmer Biomet Holdings, Lowers Price Target to $113

Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Underweight and lowers the price target from $118 to $112.

Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $112

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $130 to $125.

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $125

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $126 to $119.

Raymond James Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $119

JMP Securities analyst Andrew Boone reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Market Outperform and maintains $140 price target.

JMP Securities Reiterates Market Outperform on Zimmer Biomet Holdings, Maintains $140 Price Target

Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) from Hold to Hold.

Needham Reiterates Hold on Zimmer Biomet Holdingsto Hold

It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report <a href="https://www.benzinga.com/markets">set for Friday morning.</a>
The S&amp;P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Among the leading sectors, financial stocks outperformed after the Fed released the framework for 2025 bank stress test. The big six banks — JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), and Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) — all climbed more than 1%, with Citigroup surging 2.9%.
Eli Lilly Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) jumped 3.2% after topping earnings estimates, while Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) surged 12% and Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) skyrocketed nearly 10% on strong revenue figures. In contrast, Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) slid 4.3% on concerns over slowing smartphone demand.
Shares of Palantir Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) surged 6.5%, extending its weekly gains to 30.8%, the stock's best weekly rally since early November.
Oil prices had a volatile session. Crude initially dipped as speculation mounted over a potential Trump-Putin meeting as early as this month or next, raising hopes for possible peace talks in Ukraine. Prices rebounded after the U.S. Treasury imposed sanctions on Iran's oil network.
Gold softened, dropping 0.6% from record highs and snapping a five-session winning streak.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) remained stable, hovering just below $97,000.
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,742.18</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,082.15</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,316.14</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,811.50</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.3% to $605.83.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.2% to $447.73.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;inched 0.3% up to $528.47.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $229.55.</li>
<li>The&nbsp;Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.6%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.7%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to corporate earnings, ordered by market capitalization, are:
<ul>
<li>Eli Lilly &amp; Co.: up 3.11%</li>
<li>Linde Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NYSE">LIN</a>): up 0.34%</li>
<li>Philip Morris International Inc.: up 9.97%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): down 5.33%</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>): down 0.71%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 4.65%</li>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>): down 2.04%</li>
<li>Intercontinental Exchange Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 4.95%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>): up 2.95%</li>
<li>Yum! Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>): up 8.49%</li>
<li>Hershey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>): up 5.16%</li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>): down 2.56%</li>
<li>Qualcomm Inc.: down 4.41%</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): down 8.68%</li>
<li>O&#8217;Reilly Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>): down 1.87%</li>
<li>MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): down 1.39%</li>
<li>Cognizant Technology Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>): up 3.64%</li>
<li>Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>): down 3.92%</li>
<li>Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): down 0.07%</li>
<li>Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>): down 23.74%</li>
<li>Aflac Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): down 3.64%</li>
<li>Align Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): down 0.66%</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>): down 6.24%</li>
<li>Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>): down 3.02%</li>
<li>Aptiv Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>): up 4.18%</li>
<li>Air Products &amp; Chemicals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): down 1.75%</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>): up 0.12%</li>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>): down 6.74%</li>
</ul>
Stocks reporting after the close include: 
<ul>
<li>Amazon.com Inc. </li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</li>
<li>Fortinet Inc.</li>
<li>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
<li>Take-Two Interactive Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)</li>
<li>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>)</li>
<li>SS&amp;C Technologies Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>)</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>)</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>)</li>
<li>AptarGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>)</li>
<li>Post Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>)</li>
<li>Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</li>
<li>Boyd Gaming Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</li>
<li>Encompass Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>)</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</li>
<li>Cloudflare Inc. </li>
<li>Skechers USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>)</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)</li>
<li>Elf Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43534297/january-jobs-report-preview-speculators-bet-on-strong-payroll-surge-yet-economists-predict-a-different-picture">January Jobs Report Preview: Speculators Bet On Strong Payroll Surge, Yet Economists Predict A Different Picture</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Markets

ETFs

$BTC

AFRM

ALGN

APTV

CTSH

CTVA

SPDR Dow Jones Industrial Average ETF Trust

EXPE

ILMN

MPWR

ORLY

PINS

PLTR

POST

QCOM

SSNC

SWKS

TTWO

VRSN

XLRE

Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?

On Thursday,&nbsp;Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>)&nbsp;reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the Street estimates of $2.30.</a>
The orthopedic giant reported sales of $2.02 billion, up 4.3% on a reported basis (+4.9% on constant currency), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43522914/zimmer-biomet-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $2.014 billion</a>.
Knee product sales increased 5.1% to $839.2 million, and hip product sales increased 3% (+4% on constant currency) to $520 million.
Sports Medicine products generated sales of $489.4 million, up 8% (+8.4%).
"We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO.
Operating margin improved to 19.2% from 18.3%.
Recently, Zimmer Biomet agreed to acquire Paragon 28, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NASDAQ">FNA</a>) for an upfront cash payment of&nbsp;$13.00&nbsp;per share, corresponding to an equity value of approximately&nbsp;$1.1 billion&nbsp;and an enterprise value of <a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/43297796/zimmer-biomet-snaps-up-paragon-28-in-1-2-billion-deal-details" rel="noreferrer noopener">approximately&nbsp;$1.2 billion</a>.
Paragon 28 shareholders will also receive a contingent value right, which entitles the holder to up to&nbsp;$1.00&nbsp;per share in cash if certain revenue milestones are achieved.
Guidance: Zimmer Biomet expects fiscal year 2025 adjusted EPS of $8.15-$8.35 versus consensus of $8.55. The company expects 2025 revenue growth of 1%-3.5%.
Price Action:&nbsp;ZBH stock is down 3.13% at $104.86 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China</a></li>
</ul>

Earnings

Guidance

Movers

Why Is Zimmer Biomet Stock Trading Lower On Thursday?

Zimmer Biomet Sees FY25 Adj. EPS $8.15-$8.35 vs $7.98 Est.

Earnings Beats

Zimmer Biomet Holdings Q4 2024 Adj. EPS $2.31 Beats $2.30 Estimate, Sales $2.023B Beat $2.014B Estimate

AAMI

AGCO

AMRK

AMZN

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

DOCS

EMBC

ENTG

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Paragon 28, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>) shares are trading higher premarket on Wednesday. On Tuesday, the company inked a deal to be acquired by Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) at around $1.1 billion in equity and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43291193/zimmer-biomet-announces-definitive-agreement-to-acquire-paragon-28" rel="noreferrer noopener">$1.2 billion in enterprise value</a>.
Zimmer Biomet plans to purchase all common shares of Paragon 28 for for an upfront payment of $13.00 per share in cash.
Also, Paragon 28 shareholders will receive a non-tradeable contingent value right (CVR) of up to $1.00 per share in cash, contingent on revenue milestones.
The CVR will be payable in full or partially if net sales fall between $346 million and $361 million during Zimmer Biomet&#8217;s fiscal year 2026.
The transaction, which has been unanimously approved by the boards of directors of both companies, remains subject to regulatory approvals, Paragon 28 stockholder approval, and other customary closing conditions.
Zimmer Biomet expects the acquisition to enhance <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">its revenue growth immediately</a>.
Taking financing into account, Zimmer Biomet anticipates the transaction will be around 3% dilutive to adjusted EPS in 2025, about 1% dilutive in 2026, and accretive within 24 months of closing.
Earlier, Paragon 28 projected 2024 net revenue of $255.9 million-$256.2 million (vs. consensus of $254.6 million), reflecting a growth rate of 18.2%-<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">18.4% year-over-year</a>.
Ivan Tornos, President and Chief Executive Officer of Zimmer Biomet said, &#8220;This proposed transaction further diversifies Zimmer Biomet&#8217;s portfolio outside of core orthopedics and positions us well in one of the highest growth specialized segments in musculoskeletal care, while creating cross-selling opportunities in the rapidly growing ASC space.&#8221;
&#8220;Paragon 28&#8217;s broad and innovative foot and ankle portfolio, robust product pipeline and dedicated and highly trained sales force, combined with Zimmer Biomet&#8217;s global reach and capabilities, will uniquely position us to address the unmet patient needs of this highly complex anatomy.&#8221;
The acquisition will be funded through a combination of cash on hand and available debt financing. The deal is expected to be finalized in the first half of 2025.
Price Action: FNA shares are up 8.50% at $13.02 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43295888" target="_blank" rel="noreferrer noopener">Elizabeth Warren Pressures Trump&#8217;s Commerce Secretary Pick Howard Lutnick Over Tether Links Ahead Of Key Senate Hearing</a></li>
</ul>
Photo via Shutterstock.

Small Cap

Zimmer Biomet Snaps Up Paragon 28 In $1.2 Billion Deal: Details

Paragon 28 has announced net revenue for the full year of 2024 to be in a range of $255.9 to $256.2 million, representing 18.2% to 18.4% reported growth over the prior fiscal year.&nbsp;
Zimmer Biomet expects the proposed transaction, considering the impact of financing, to be approximately 3% dilutive to adjusted earnings per share in 2025, about 1% dilutive to 2026 adjusted earnings per share and accretive to adjusted earnings per share within 24 months of deal close.
Zimmer Biomet plans to fund the proposed transaction through a combination of cash on the balance sheet and other available debt financing sources. Zimmer Biomet expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Zimmer Biomet Expects Proposed Paragon 28 Transaction To Immediately Accelerate Revenue Growth And To Be Approximately 3% Dilutive To Adjusted EPS In 2025

Dividends

Press Releases

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2025

Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger

Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference

Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur

Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting

Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System

PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Truist Securities

Barclays

RBC Capital

Raymond James

JMP Securities

Screenshot 2024-03-27 at 5.33.58 PM

NMTC

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Comments

Zimmer Biomet Holdings

뉴스

파트너 / 기고자

벤징가 글로벌